Pfizer Has 41% Of Arthritis Market Post-Vioxx
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and FDA have agreed to "black box" for Bextra skin reactions and will address safety in post-op patients "separately" in new labeling. Pfizer plans NDA for parecoxib by the end of the year.